24243-71-8

Basic information

• Product Name: PROPANE-1-SULFONAMIDE
• Synonyms: PROPANE-1-SULFONAMIDE;PROPANE-1-SULPHONAMIDE;1-Propanesulfonamide;Propane-1-sulphonamide 97%;1-(Sulphamoyl)propane;Propane-1-sulphonamide97%
• CAS NO: 24243-71-8
• Molecular Formula: C₃H₉NO₂S
• Molecular Weight: 123.17
• Mol File: 24243-71-8.mol
• Article Data: 8

Chemical Properties

• Melting Point: 51-52
• Boiling Point: 226.7 °C at 760 mmHg
• Flash Point: 90.9 °C
• Appearance: /
• Density: 1.198 g/cm³
• Vapor Pressure: 0.0805mmHg at 25°C
• Refractive Index: 1.464
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
• PKA: 10.87±0.60(Predicted)
• CAS DataBase Reference: PROPANE-1-SULFONAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: PROPANE-1-SULFONAMIDE(24243-71-8)
• EPA Substance Registry System: PROPANE-1-SULFONAMIDE(24243-71-8)

Safety Data

• Hazard Codes: T
• Hazardous Substances Data: 24243-71-8(Hazardous Substances Data)

Usage

Uses

Propylsulfonamide is used in the preparation of different electron donors in luminogenic luciferins and fluorescent dyes.

InChI:InChI=1/C3H9NO2S/c1-2-3-7(4,5)6/h2-3H2,1H3,(H2,4,5,6)

Upstream product

• 10147-36-1 n-propanesulfonyl chloride 
• 1120-71-4 1,3-propanesultone 

Downstream Products

• 35578-28-0 3-chloro-propane-1-sulfonic acid amide 
• 855479-54-8 tert-butyl [3-[3'-(cyclohexyloxy)-4'-[[(propylsulfonyl)amino]carbonyl]-4-biphenylyl]propyl][(2R)-2-hydroxy-2-phenylethyl]carbamate 
• 1304515-71-6 C₂₂H₂₉F₃N₄O₂S 
• 139668-86-3 N-(4-chlorophenyl)-N'-1-propanesulfonylurea 
• 76-19-7 freon-218 
• 76-16-4 Hexafluoroethane 
• 754-03-0 ethanesulfonyl fluoride 
• 423-40-5 1-perfluoropropanesulfonyl fluoride 

Relevant articles and documents

THIAZOLIDINONE COMPOUNDS AND USE THEREOF

A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.

QUINOXALINE COMPOUNDS AND USE THEREOF

The present invention is related to quinoxaline compounds of Formula (I) in particular for the treatment of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.

Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases

An isovaleramide analog having at least one of an increased potency, an increased half-life, and an increased stability compared to isovaleramide. The isovaleramide analog is a cyclic analog or a noncyclic analog. The isovaleramide analog is formulated into a pharmaceutical composition. A method of treating a central nervous system condition or disease is also disclosed. The method comprises administering an isovaleramide analog to a patient suffering from the central nervous system condition or disease.